Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review)
Int J Oncol. 2024 Apr;64(4):40. doi: 10.3892/ijo.2024.5628. Epub 2024 Feb 23.ABSTRACTOsteosarcoma (OS) is a frequently occurring primary bone tumor, mostly affecting children, adolescents and young adults. Before 1970, surgical resection was the main treatment method for OS, but the clinical results were not promising. Subsequently, the advent of chemotherapy has improved the prognosis of patients with OS. However, there is still a high incidence of metastasis or recurrence, and chemotherapy has several side effects, thus making the 5‑year survival rate markedly low. Recently, chimeric antigen receptor T (CAR‑T) cell t...
Source: International Journal of Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Tong Yu Weibo Jiang Yang Wang Ying Zhou Jianhang Jiao Minfei Wu Source Type: research
Xenograft and organoid models in developing precision medicine for gastric cancer (Review)
Int J Oncol. 2024 Apr;64(4):41. doi: 10.3892/ijo.2024.5629. Epub 2024 Feb 23.ABSTRACTGastric cancer (GC), a highly heterogeneous disease, has diverse histological and molecular subtypes. For precision medicine, well‑characterized models encompassing the full spectrum of subtypes are necessary. Patient‑derived tumor xenografts and organoids serve as important preclinical models in GC research. The main advantage of these models is the retention of phenotypic and genotypic heterogeneity present in parental tumor tissues. Utilizing diverse sequencing techniques and preclinical models for GC research facilitates accuracy i...
Source: International Journal of Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Jiao Xu Bixin Yu Fan Wang Jin Yang Source Type: research
HER2 < sup > + < /sup > advanced gastric cancer: Current state and opportunities (Review)
Int J Oncol. 2024 Apr;64(4):36. doi: 10.3892/ijo.2024.5624. Epub 2024 Feb 23.ABSTRACTHuman epidermal growth factor receptor 2 (HER2)+ gastric cancer (GC) is a distinct subtype of GC, accounting for 10‑20% of all cases of GC. Although the development of the anti‑HER2 monoclonal antibody trastuzumab has markedly improved response rates and prognosis of patients with HER2+ advanced GC (AGC), drug resistance remains a considerable challenge. Therefore, dynamic monitoring of HER2 expression levels can facilitate the identification of patients who may benefit from targeted therapy. Besides trastuzumab, DS‑8201 and RC48 hav...
Source: International Journal of Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Hui-Hui Hu Sai-Qi Wang Huichen Zhao Zhe-Sheng Chen Xiaojing Shi Xiao-Bing Chen Source Type: research
Advancements in colorectal cancer research: Unveiling the cellular and molecular mechanisms of neddylation (Review)
Int J Oncol. 2024 Apr;64(4):39. doi: 10.3892/ijo.2024.5627. Epub 2024 Feb 23.ABSTRACTNeddylation, akin to ubiquitination, represents a post‑translational modification of proteins wherein neural precursor cell‑expressed developmentally downregulated protein 8 (NEDD8) is modified on the substrate protein through a series of reactions. Neddylation plays a pivotal role in the growth and proliferation of animal cells. In colorectal cancer (CRC), it predominantly contributes to the proliferation, metastasis and survival of tumor cells, decreasing overall patient survival. The strategic manipulation of the NEDD8‑mediated ne...
Source: International Journal of Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Tianyu Wang Xiaobing Li Ruijie Ma Jian Sun Shuhong Huang Zhigang Sun Meng Wang Source Type: research
A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer (Review)
Int J Oncol. 2024 Apr;64(4):38. doi: 10.3892/ijo.2024.5626. Epub 2024 Feb 23.ABSTRACTLung cancer represents a marked global public health concern. Despite existing treatment modalities, the average 5‑year survival rate for patients with patients with lung cancer is only ~20%. As there are numerous adverse effects of systemic administration routes, there is an urgent need to develop a novel therapeutic strategy tailored specifically for patients with lung cancer. Non‑invasive aerosol inhalation, as a route of drug administration, holds unique advantages in the context of respiratory diseases. Nanoscale materials have ex...
Source: International Journal of Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Lixin Xie Daihan Xie Zhefei Du Shaobo Xue Kesheng Wang Xin Yu Xiuli Liu Qiuxia Peng Chao Fang Source Type: research
Cucurbitacin IIa promotes the immunogenic cell death ‑inducing effect of doxorubicin and modulates immune microenvironment in liver cancer
Int J Oncol. 2024 Apr;64(4):37. doi: 10.3892/ijo.2024.5625. Epub 2024 Feb 23.ABSTRACTThe immunogenic cell death (ICD) has aroused great interest in cancer immunotherapy. Doxorubicin (DOX), which can induce ICD, is a widely used chemotherapeutic drug in liver cancer. However, DOX‑induced ICD is not potent enough to initiate a satisfactory immune response. Cucurbitacin IIa (CUIIa), a tetracyclic triterpene, is a biologically active compound present in the Cucurbitaceae family. The present study assessed the effects of the combination of DOX and CUIIa on the viability, colony formation, apoptosis and cell cycle of HepG2 cel...
Source: International Journal of Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Sujuan Li Sen Wang Anping Zhang Lixia Luo Jie Song Guoli Wei Zhijun Fang Source Type: research
Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review)
Int J Oncol. 2024 Apr;64(4):40. doi: 10.3892/ijo.2024.5628. Epub 2024 Feb 23.ABSTRACTOsteosarcoma (OS) is a frequently occurring primary bone tumor, mostly affecting children, adolescents and young adults. Before 1970, surgical resection was the main treatment method for OS, but the clinical results were not promising. Subsequently, the advent of chemotherapy has improved the prognosis of patients with OS. However, there is still a high incidence of metastasis or recurrence, and chemotherapy has several side effects, thus making the 5‑year survival rate markedly low. Recently, chimeric antigen receptor T (CAR‑T) cell t...
Source: International Journal of Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Tong Yu Weibo Jiang Yang Wang Ying Zhou Jianhang Jiao Minfei Wu Source Type: research
Xenograft and organoid models in developing precision medicine for gastric cancer (Review)
Int J Oncol. 2024 Apr;64(4):41. doi: 10.3892/ijo.2024.5629. Epub 2024 Feb 23.ABSTRACTGastric cancer (GC), a highly heterogeneous disease, has diverse histological and molecular subtypes. For precision medicine, well‑characterized models encompassing the full spectrum of subtypes are necessary. Patient‑derived tumor xenografts and organoids serve as important preclinical models in GC research. The main advantage of these models is the retention of phenotypic and genotypic heterogeneity present in parental tumor tissues. Utilizing diverse sequencing techniques and preclinical models for GC research facilitates accuracy i...
Source: International Journal of Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Jiao Xu Bixin Yu Fan Wang Jin Yang Source Type: research
HER2 < sup > + < /sup > advanced gastric cancer: Current state and opportunities (Review)
Int J Oncol. 2024 Apr;64(4):36. doi: 10.3892/ijo.2024.5624. Epub 2024 Feb 23.ABSTRACTHuman epidermal growth factor receptor 2 (HER2)+ gastric cancer (GC) is a distinct subtype of GC, accounting for 10‑20% of all cases of GC. Although the development of the anti‑HER2 monoclonal antibody trastuzumab has markedly improved response rates and prognosis of patients with HER2+ advanced GC (AGC), drug resistance remains a considerable challenge. Therefore, dynamic monitoring of HER2 expression levels can facilitate the identification of patients who may benefit from targeted therapy. Besides trastuzumab, DS‑8201 and RC48 hav...
Source: International Journal of Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Hui-Hui Hu Sai-Qi Wang Huichen Zhao Zhe-Sheng Chen Xiaojing Shi Xiao-Bing Chen Source Type: research
Advancements in colorectal cancer research: Unveiling the cellular and molecular mechanisms of neddylation (Review)
Int J Oncol. 2024 Apr;64(4):39. doi: 10.3892/ijo.2024.5627. Epub 2024 Feb 23.ABSTRACTNeddylation, akin to ubiquitination, represents a post‑translational modification of proteins wherein neural precursor cell‑expressed developmentally downregulated protein 8 (NEDD8) is modified on the substrate protein through a series of reactions. Neddylation plays a pivotal role in the growth and proliferation of animal cells. In colorectal cancer (CRC), it predominantly contributes to the proliferation, metastasis and survival of tumor cells, decreasing overall patient survival. The strategic manipulation of the NEDD8‑mediated ne...
Source: International Journal of Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Tianyu Wang Xiaobing Li Ruijie Ma Jian Sun Shuhong Huang Zhigang Sun Meng Wang Source Type: research
A novel therapeutic outlook: Classification, applications and challenges of inhalable micron/nanoparticle drug delivery systems in lung cancer (Review)
Int J Oncol. 2024 Apr;64(4):38. doi: 10.3892/ijo.2024.5626. Epub 2024 Feb 23.ABSTRACTLung cancer represents a marked global public health concern. Despite existing treatment modalities, the average 5‑year survival rate for patients with patients with lung cancer is only ~20%. As there are numerous adverse effects of systemic administration routes, there is an urgent need to develop a novel therapeutic strategy tailored specifically for patients with lung cancer. Non‑invasive aerosol inhalation, as a route of drug administration, holds unique advantages in the context of respiratory diseases. Nanoscale materials have ex...
Source: International Journal of Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Lixin Xie Daihan Xie Zhefei Du Shaobo Xue Kesheng Wang Xin Yu Xiuli Liu Qiuxia Peng Chao Fang Source Type: research
Cucurbitacin IIa promotes the immunogenic cell death ‑inducing effect of doxorubicin and modulates immune microenvironment in liver cancer
Int J Oncol. 2024 Apr;64(4):37. doi: 10.3892/ijo.2024.5625. Epub 2024 Feb 23.ABSTRACTThe immunogenic cell death (ICD) has aroused great interest in cancer immunotherapy. Doxorubicin (DOX), which can induce ICD, is a widely used chemotherapeutic drug in liver cancer. However, DOX‑induced ICD is not potent enough to initiate a satisfactory immune response. Cucurbitacin IIa (CUIIa), a tetracyclic triterpene, is a biologically active compound present in the Cucurbitaceae family. The present study assessed the effects of the combination of DOX and CUIIa on the viability, colony formation, apoptosis and cell cycle of HepG2 cel...
Source: International Journal of Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Sujuan Li Sen Wang Anping Zhang Lixia Luo Jie Song Guoli Wei Zhijun Fang Source Type: research
Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review)
Int J Oncol. 2024 Apr;64(4):40. doi: 10.3892/ijo.2024.5628. Epub 2024 Feb 23.ABSTRACTOsteosarcoma (OS) is a frequently occurring primary bone tumor, mostly affecting children, adolescents and young adults. Before 1970, surgical resection was the main treatment method for OS, but the clinical results were not promising. Subsequently, the advent of chemotherapy has improved the prognosis of patients with OS. However, there is still a high incidence of metastasis or recurrence, and chemotherapy has several side effects, thus making the 5‑year survival rate markedly low. Recently, chimeric antigen receptor T (CAR‑T) cell t...
Source: International Journal of Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Tong Yu Weibo Jiang Yang Wang Ying Zhou Jianhang Jiao Minfei Wu Source Type: research
Xenograft and organoid models in developing precision medicine for gastric cancer (Review)
Int J Oncol. 2024 Apr;64(4):41. doi: 10.3892/ijo.2024.5629. Epub 2024 Feb 23.ABSTRACTGastric cancer (GC), a highly heterogeneous disease, has diverse histological and molecular subtypes. For precision medicine, well‑characterized models encompassing the full spectrum of subtypes are necessary. Patient‑derived tumor xenografts and organoids serve as important preclinical models in GC research. The main advantage of these models is the retention of phenotypic and genotypic heterogeneity present in parental tumor tissues. Utilizing diverse sequencing techniques and preclinical models for GC research facilitates accuracy i...
Source: International Journal of Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Jiao Xu Bixin Yu Fan Wang Jin Yang Source Type: research
HER2 < sup > + < /sup > advanced gastric cancer: Current state and opportunities (Review)
Int J Oncol. 2024 Apr;64(4):36. doi: 10.3892/ijo.2024.5624. Epub 2024 Feb 23.ABSTRACTHuman epidermal growth factor receptor 2 (HER2)+ gastric cancer (GC) is a distinct subtype of GC, accounting for 10‑20% of all cases of GC. Although the development of the anti‑HER2 monoclonal antibody trastuzumab has markedly improved response rates and prognosis of patients with HER2+ advanced GC (AGC), drug resistance remains a considerable challenge. Therefore, dynamic monitoring of HER2 expression levels can facilitate the identification of patients who may benefit from targeted therapy. Besides trastuzumab, DS‑8201 and RC48 hav...
Source: International Journal of Oncology - February 23, 2024 Category: Cancer & Oncology Authors: Hui-Hui Hu Sai-Qi Wang Huichen Zhao Zhe-Sheng Chen Xiaojing Shi Xiao-Bing Chen Source Type: research
